2. Search Result
Search Result
Results for "

splice

" in MedChemExpress (MCE) Product Catalog:

153

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

10

Natural
Products

1

Recombinant Proteins

3

Isotope-Labeled Compounds

8

Antibodies

20

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12248
    Telaglenastat
    Maximum Cited Publications
    104 Publications Verification

    CB-839

    		 Glutaminase Autophagy Cancer
    Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
    Telaglenastat
  • HY-16399
    Pladienolide B
    5 Publications Verification

    		 Apoptosis SF3B1 Cancer
    Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis .
    Pladienolide B
  • HY-N2117
    Isoginkgetin
    Maximum Cited Publications
    20 Publications Verification

    		 MMP Akt NF-κB Proteasome Apoptosis Autophagy Inflammation/Immunology Cancer
    Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .
    Isoginkgetin
  • HY-109101
    Risdiplam
    5+ Cited Publications

    RG7916; RO7034067

    		 DNA/RNA Synthesis Neurological Disease
    Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .
    Risdiplam
  • HY-N2360
    Hinokiflavone
    5+ Cited Publications

    		 E1/E2/E3 Enzyme Apoptosis MMP ClpP Infection Inflammation/Immunology Cancer
    Hinokiflavone is a novel modulator of pre-mRNA splicing activity extracted from plants with anti-inflammatory, anti-tumor and antiviral activities. Hinokiflavone is also a potent inhibitor for matrix metalloproteinases (MMPs). Hinokiflavone attenuates the virulence of Methicillin (HY-121544)-resistant staphylococcus aureus by inhibiting caseinolytic protease P (ClpP) with an IC50 value of 34.36 mg/mL. Hinokiflavone induces apoptosis via the reactive oxygen species-mitochondria-mediated apoptotic pathway and inhibits tumor cell migration and invasion. Hinokiflavone is a SUMO protease inhibitor against sentrin-specific protease 1 (SENP1) activity .
    Hinokiflavone
  • HY-19620
    Branaplam
    10+ Cited Publications

    LMI070; NVS-SM1

    		 DNA/RNA Synthesis Potassium Channel Cancer
    Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
    Branaplam
  • HY-104040
    MKC8866
    15+ Cited Publications

    Orin1001

    		 IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866
  • HY-112980
    Nusinersen
    4 Publications Verification

    		 DNA/RNA Synthesis Neurological Disease
    Nusinersen is an antisense oligonucleotide active molecule. Nusinersen modifies the pre-messenger RNA splicing of the SMN2 gene, thereby promoting the production of full-length SMN protein. Nusinersen improves spinal muscular atrophy .
    Nusinersen
  • HY-16466
    Spliceostatin A

    		SF3B1 Cancer
    Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .
    Spliceostatin A
  • HY-112980A
    Nusinersen sodium
    4 Publications Verification

    		 DNA/RNA Synthesis Neurological Disease
    Nusinersen sodium is an antisense oligonucleotide active molecule. Nusinersen sodium modifies the pre-messenger RNA splicing of the SMN2 gene, thereby promoting the production of full-length SMN protein. Nusinersen sodium improves spinal muscular atrophy .
    Nusinersen sodium
  • HY-N1943
    Ailanthone
    2 Publications Verification

    Δ13-Dehydrochaparrinone

    		 Androgen Receptor Inflammation/Immunology Cancer
    Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC50=69 nM) and constitutively active truncated AR splice variants (AR1-651 IC50=309 nM).
    Ailanthone
  • HY-100236
    Madrasin
    5+ Cited Publications

    DDD00107587

    		 DNA/RNA Synthesis Cancer
    Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells .
    Madrasin
  • HY-132611
    Golodirsen

    SRP-4053

    		 Dystrophin DNA/RNA Synthesis Neurological Disease
    Golodirsen (SRP-4053) is an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO). Golodirsen restores the reading frame of the Duchenne muscular dystrophy (DMD) gene by modifying the splicing process of the pre-mRNA, skipping exon 53. Golodirsen can restore the expression of the anti-myostatin protein. Golodirsen can be used for the research of duchenne muscular dystrophy (DMD) .
    Golodirsen
  • HY-19620A
    Branaplam hydrochloride
    10+ Cited Publications

    LMI070 hydrochloride; NVS-SM1 hydrochloride

    		 DNA/RNA Synthesis Potassium Channel Cancer
    Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .
    Branaplam hydrochloride
  • HY-15338
    TG003
    5+ Cited Publications

    		 CDK Cancer
    TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
    TG003
  • HY-P3522
    REDV

    		Integrin Cardiovascular Disease
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .
    REDV
  • HY-101792
    RG7800
    5 Publications Verification

    RO6885247

    		 DNA/RNA Synthesis Others
    RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.
    RG7800
  • HY-117389
    Homocarbonyltopsentin

    PK4C9

    		 DNA/RNA Synthesis Others
    Homocarbonyltopsentin (PK4C9) is a small-molecule TSL2-binding compound, binds to pentaloop conformations of TSL2 and promotes a shift to triloop conformations that display enhanced SMN2 exon 7 (E7) splicing with EC50 value of 16 μM .
    Homocarbonyltopsentin
  • HY-P5960
    PTBP1-RNA-binding inhibitor P6 TFA

    PTBP1 α3-helix derived peptide P6 TFA

    		 DNA/RNA Synthesis Others
    PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .
    PTBP1-RNA-binding inhibitor P6 TFA
  • HY-141881
    PROTAC-O4I2

    		PROTACs Apoptosis SF3B1 Cancer
    PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC50 value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .
    PROTAC-O4I2
  • HY-157261
    UNC2383

    		Biochemical Assay Reagents Endocrinology
    UNC2383 is an oligonucleotide enhancer compound. UNC2383 can enhance the efficacy of antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs). UNC2383 can be used in research of diseases involving impaired oligonucleotide delivery, such as cystic fibrosis .
    UNC2383
  • HY-145724
    Drisapersen

    Kyndrisa; GSK2402968A; PRO051

    		 DNA/RNA Synthesis Dystrophin Neurological Disease
    Drisapersen (Kyndrisa) is a 2 '-O-methyl phosphorothioate RNA antisense oligonucleotide that induces exon 51 skipping. Drisapersen induces skipping of exon 51 during Dystrophin pre-mRNA splicing, allowing the synthesis of partially functional Dystrophin. Drisapersen can be used in research related to Duchenne muscular dystrophy .
    Drisapersen
  • HY-147149
    BPN-15477

    		DNA/RNA Synthesis Neurological Disease
    BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .
    BPN-15477
  • HY-148384
    UHMCP1

    		Fluorescent Dye Cancer
    UHMCP1 is a chemical probe of U2AF homology motifs (UHM) with a Kd of 79 μM. UHMCP1 prevents the SF3b155/U2AF65 interaction, impacts RNA splicing and cell viability. UHMCP1 has potential anticancer properties .
    UHMCP1
  • HY-18509
    IRE1α kinase-IN-2
    1 Publications Verification

    		 IRE1 Cancer
    IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC50 of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC50=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines .
    IRE1α kinase-IN-2
  • HY-150248
    RNA splicing modulator 3

    		DNA/RNA Synthesis Others
    RNA splicing modulator 3 (compound 236) is a RNA splicing modulator, with an AC50 value of <100 nM .
    RNA splicing modulator 3
  • HY-149433
    BWA-522

    		PROTACs Androgen Receptor Apoptosis Cancer
    BWA-522 is an orally active PROTAC degrader targeting full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7). BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor, suppresses AR downstream signaling proteins and induces cancer cells apoptosis. BWA-522 inhibits tumor growth in LNCaP xenograft mouse model. BWA-522 can be used for the research of prostate cancer .
    BWA-522
  • HY-126076
    VPC-80051 racemate
    1 Publications Verification

    		 Drug Isomer DNA/RNA Synthesis Others
    VPC-80051 racemate is a racemate of VPC-80051. VPC-80051 is a prototype inhibitor of the hnRNP A1 splicing factor .
    VPC-80051 racemate
  • HY-112633
    SMN-C3

    		DNA/RNA Synthesis Others
    SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA).
    SMN-C3
  • HY-148772
    PTC258

    		DNA/RNA Synthesis Neurological Disease
    PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model .
    PTC258
  • HY-117960
    Orismilast

    LEO-32731

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .
    Orismilast
  • HY-150102
    EPI-7170
    1 Publications Verification

    		 Androgen Receptor Cancer
    EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .
    EPI-7170
  • HY-126076A
    VPC-80051

    		DNA/RNA Synthesis Cancer
    VPC-80051 is an inhibitor of hnRNP A1 splicing activity. VPC-80051 directly interacts with hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line. VPC-80051 can be used in prostate cancer research .
    VPC-80051
  • HY-19828
    Herboxidiene

    GEX1A

    		 DNA/RNA Synthesis Cancer
    Herboxidiene (GEX1A) is a potent phytotoxic polyketide from Streptomyces sp. A7847 with a diverse range of activities, including herbicidal, anti-cholesterol, anti-tumor effects. Herboxidiene inhibits the pre-mRNA splicing process by binding to spliceosome-associated protein (SAP) 155, a subunit of SF3b, in the splicesome .
    Herboxidiene
  • HY-177360
    RNA splicing modulator-4

    		DNA/RNA Synthesis Neurological Disease Cancer
    RNA splicing modulator-4 is an RNA splicing modulator. RNA splicing modulator-4 controls the inclusion or exclusion of specific exons in precursor mRNA (pre-mRNA) by regulating alternative splicing events, thereby altering the coding sequence and function of mature mRNA. RNA splicing modulator-4 shows promise for research into neurodegenerative diseases (such as Huntington's disease) and cancers .
    RNA splicing modulator-4
  • HY-111520
    NVS-SM2

    		DNA/RNA Synthesis Neurological Disease
    NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC50 of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .
    NVS-SM2
  • HY-150246
    RNA splicing modulator 1

    		DNA/RNA Synthesis Others
    RNA splicing modulator 1 (compound 233) is a RNA splicing modulator, with an AC50 value of <100 nM .
    RNA splicing modulator 1
  • HY-144399
    CD33 splicing modulator 1

    		Transmembrane Glycoprotein Neurological Disease
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease .
    CD33 splicing modulator 1
  • HY-101792A
    RG7800 tetrahydrochloride
    5 Publications Verification

    RO6885247 tetrahydrochloride

    		 DNA/RNA Synthesis Neurological Disease
    RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.
    RG7800 tetrahydrochloride
  • HY-135784
    OSMI-2
    1 Publications Verification

    		 OGT Acyltransferase Metabolic Disease
    OSMI-2 (Compound 1b) is a cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-2 increases detained intron splicing in cells .
    OSMI-2
  • HY-153736
    NSC 194308

    		DNA/RNA Synthesis Cancer
    NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .
    NSC 194308
  • HY-124648
    SMN-C2

    		DNA/RNA Synthesis Inflammation/Immunology
    SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .
    SMN-C2
  • HY-15338A
    (E/Z)-TG003

    		CDK Cancer
    (E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
    (E/Z)-TG003
  • HY-147412
    Ultevursen

    QR-421a

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Neurological Disease
    Ultevursen (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .
    Ultevursen
  • HY-155874
    ZNL-05-044

    		CDK Cancer
    ZNL-05-044 is a CDK11 inhibitor with an IC50s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay). ZNL-05-044 leads to G2/M cell cycle arrest and impairs RNA splicing .
    ZNL-05-044
  • HY-P990782
    Efzofitimod

    		Aminoacyl-tRNA Synthetase Inflammation/Immunology
    Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
    Efzofitimod
  • HY-E70372
    SUMO Protease

    		Biochemical Assay Reagents Others
    SUMO Protease is highly specific for proteins containing small ubiquitin-like modifier (SUMO) tags. SUMO Protease can be used to regulates the proteins splicing, controlls protein structure and function in vitro .
    SUMO Protease
  • HY-12248R
    Telaglenastat (Standard)

    CB-839 (Standard)

    		 Glutaminase Autophagy Reference Standards Cancer
    Telaglenastat (Standard) is the analytical standard of Telaglenastat. This product is intended for research and analytical applications. Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .
    Telaglenastat (Standard)
  • HY-136951
    cp028

    		DNA/RNA Synthesis Cancer
    cp028 is a potent pre-mRNA splicing inhibitor. cp028 inhibits splicing in HeLa nuclear extract with an IC50 value of 54 µM .
    cp028
  • HY-134851
    HIV-1 inhibitor-6
    1 Publications Verification

    		 HIV Infection
    HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM .
    HIV-1 inhibitor-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: